Amneal Pharmaceuticals, Inc. $AMRX Position Boosted by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 2,866.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 784,803 shares of the company’s stock after buying an additional 758,343 shares during the period. SG Americas Securities LLC’s holdings in Amneal Pharmaceuticals were worth $9,889,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in AMRX. Comerica Bank boosted its holdings in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the period. Exchange Traded Concepts LLC purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter worth approximately $31,000. Focus Partners Wealth purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter worth approximately $42,000. Advisory Services Network LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $50,000. Finally, Bellevue Group AG acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $79,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $11.85 on Monday. The firm has a 50 day moving average of $13.59 and a two-hundred day moving average of $12.19. Amneal Pharmaceuticals, Inc. has a 12 month low of $6.68 and a 12 month high of $15.42. The company has a market capitalization of $3.73 billion, a price-to-earnings ratio of 51.52 and a beta of 1.34.

Analyst Upgrades and Downgrades

AMRX has been the topic of a number of research reports. Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Truist Financial boosted their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Barclays initiated coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $14.20.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.